Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

7 terminated/withdrawn out of 35 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

2 trials in Phase 3/4

Results Transparency

2 of 25 completed trials have results

Key Signals

2 with results6 terminated

Enrollment Performance

Analytics

Phase 2

16(47.1%)

Phase 1

15(44.1%)

Phase 3

2(5.9%)

N/A

1(2.9%)

34Total

Phase 2(16)

Phase 1(15)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT04597411Phase 1Active Not Recruiting

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Role: lead

NCT03511664Phase 3Completed

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Role: lead

NCT04430192Phase 1Active Not Recruiting

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Role: collaborator

NCT04419402Phase 2Active Not Recruiting

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT01689766Phase 2Completed

Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma

Role: lead

NCT01684098Phase 2Completed

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Role: lead

NCT01686256Phase 1Completed

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

Role: lead

NCT01689714Phase 2Completed

Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma

Role: lead

NCT01689636Phase 1Completed

Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients

Role: lead

NCT01689727Phase 2Completed

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Role: lead

NCT01689662Phase 2Completed

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma

Role: lead

NCT03392428Phase 2Completed

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT01170650Phase 3Terminated

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Role: lead

NCT00003763Not ApplicableCompleted

Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer

Role: lead

NCT03494114Phase 1Terminated

Imaging Activated Macrophages in the Lungs

Role: collaborator

NCT01002924Phase 2Completed

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

Role: lead

NCT01577654Phase 2Completed

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

Role: lead

NCT03042312Phase 2Terminated

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

Role: lead

NCT02202447Phase 1Completed

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Role: lead

NCT03011320Phase 1Completed

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

Role: lead